Table 3.

Sensitivity analysis for the assessment of the relationship between statin consumption and risk of developing AMD.

First author	Year	OR (95% CI)	p value
Klein [20]	2003	0.92 (0.82–1.04)	0.125
McGwin [31]	2003	0.98 (0.88–1.08)	0.314
McGwin [6]	2005	0.94 (0.83–1.05)	0.227
Smeeth [32]	2005	0.92 (0.81–1.05)	0.211
McGwin [33]	2006	0.91 (0.80–1.02)	0.116
Klein [21]	2007	0.94 (0.84–1.06)	0.249
Tan [22]	2007	0.94 (0.83–1.05)	0.266
Cackett [38]	2008	0.92 (0.82–1.04)	0.124
Etminan [34]	2008	0.91 (0.80–1.02)	0.091
Kaiserman [35]	2009	0.92 (0.81–1.04)	0.115
Maguire [23]	2009	0.91 (0.81–1.04)	0.136
Smeeth [24]	2009	0.91 (0.80–1.03)	0.154
Fong [36]	2010	0.92 (0.82–1.05)	0.209
Shalev [25]	2011	0.92 (0.81–1.04)	0.115
VanderBeek [26]	2013	0.92 (0.81–1.05)	0.135
Barbosa [39]	2014	0.95 (0.84–1.07)	0.284
Cougnard-Gregoire [27]	2014	0.92 (0.81–1.04)	0.109
Al-Holou [28]	2015	0.93 (0.83–1.05)	0.275
Cruickshanks [29]	2017	0.94 (0.84–1.06)	0.244
Lee [37]	2019	0.91 (0.80–1.04)	0.322
Rajeshuni [40]	2019	0.91 (0.80–1.03)	0.165
Ludwig [30]	2021	0.93 (0.82–1.05)	0.205